The global antacids market size is calculated at USD 7.44 billion in 2024, grew to USD 7.68 billion in 2025, and is predicted to hit around USD 10.29 billion by 2034, poised to grow at a CAGR of 3.3% between 2024 and 2034. The North America antacids market size accounted for USD 3.42 billion in 2024 and is anticipated to grow at the fastest CAGR of 3.35% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antacids Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antacids Market Revenue and Volume, by Mechanism of Action, 2024-2034
8.1.1 Systemic Antacids
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Non-systemic Antacids
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Antacids Market Revenue and Volume, by Formulation Type, 2024-2034
9.1.1. Tablets
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Liquids
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Antacids Market Revenue and Volume, by Distribution Channel, 2024-2034
10.1.1. Hospital pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Drug stores and retail pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Online providers
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Formulation Type (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
12.1. Infirst Healthcare Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bayer AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abbott Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cipla Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Reckitt Benckiser Group PLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WellSpring Pharmaceutical Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Prestige Consumer Healthcare Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Alkem Laboratories Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Haleon plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample